Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biohaven Ltd
(NY:
BHVN
)
35.98
+1.27 (+3.66%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biohaven Ltd
< Previous
1
2
3
4
5
6
7
8
Next >
Mid-Day Market Update: U.S. Stocks Turn Lower; Biohaven Pharmaceutical Shares Jump
May 10, 2022
U.S. stocks turned mostly lower midway through trading, with the Dow Jones dropping more than 100 points on Tuesday.
Via
Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
May 10, 2022
Gainers
Via
Benzinga
Recap: Biohaven Pharma Hldgs Q1 Earnings
May 10, 2022
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Where Biohaven Pharma Hldgs Stands With Analysts
January 07, 2022
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'
May 10, 2022
One analyst says the deal "couldn't have come at a better time." Here's why.
Via
Investor's Business Daily
Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know
May 10, 2022
Via
Benzinga
BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders
May 10, 2022
From
Halper Sadeh LLP
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 10, 2022
Via
Benzinga
Pfizer to Acquire Biohaven Pharmaceuticals
May 10, 2022
From
Pfizer Inc.
Via
Business Wire
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine
April 27, 2022
European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who...
Via
Benzinga
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
April 27, 2022
From
Pfizer Inc.
Via
Business Wire
Axsome Therapeutics' Good Fortune Reverses As Its Migraine Drug Hits A Hurdle
April 25, 2022
Last week, Axsome stock soared on its depression drug. This week is a different story.
Via
Investor's Business Daily
AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship
April 13, 2022
Flagship Pioneering is swiping one of AbbVie's biggest names.
Via
Investor's Business Daily
Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90
April 06, 2022
On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago.
Via
Investor's Business Daily
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
Biohaven Pharmaceutical's Return On Capital Employed Insights
February 28, 2022
Biohaven Pharmaceutical (NYSE:BHVN) brought in sales totaling $190.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 15.81%, resulting...
Via
Benzinga
Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals
February 25, 2022
Biohaven inked a pair of deals that one analyst find promising for its pipeline.
Via
Investor's Business Daily
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals
February 25, 2022
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has entered into a global license agreement with Bristol Myers Squibb & Co (NYSE: BMY) to...
Via
Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
February 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To...
Via
Benzinga
Biohaven Pharma: Q4 Earnings Insights
February 25, 2022
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q4 earnings results on Friday, February 25, 2022 at 07:30 AM. Here's what investors need to know about the announcement....
Via
Benzinga
Earnings Scheduled For February 25, 2022
February 25, 2022
Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •...
Via
Benzinga
Biohaven Pharmaceutical's Earnings Outlook
February 24, 2022
Biohaven Pharmaceutical (NYSE:BHVN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints
February 14, 2022
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) reported topline results from an Asia-Pacific, Phase 3 trial of...
Via
Benzinga
New Psychedelics ETF Launches On NYSE Arca
February 02, 2022
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...
Via
Benzinga
This Tattooed, Cowboy-Boot-Wearing Top CEO Refuses To Go Clean Cut
January 20, 2022
John Chiminski knows he doesn't fit the traditional image of a corporate bigwig. And the Catalent CEO is not about to change.
Via
Investor's Business Daily
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
January 06, 2022
Via
AB Newswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.